Patents by Inventor Jimmy Andrew Rotolo

Jimmy Andrew Rotolo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for Treating GI Syndrome and Graft versus Host Disease
    Publication number: 20140112932
    Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
    Type: Application
    Filed: August 23, 2013
    Publication date: April 24, 2014
    Applicants: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Jimmy Andrew Rotolo, Richard N. Kolesnick, Renata Pasqualini, Wadih Arap
  • Methods for treating GI syndrome and graft versus host disease
    Patent number: 8562993
    Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: October 22, 2013
    Assignees: Board of Regents the University of Texas System, Sloan Kettering Institute for Cancer Research
    Inventors: Jimmy Andrew Rotolo, Richard Kolesnick, Renata Pasqualini, Wadih Arap
  • METHODS FOR TREATING AND PREVENTING GI SYNDROME AND GRAFT VERSUS HOST DISEASE
    Publication number: 20100239572
    Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
    Type: Application
    Filed: May 6, 2008
    Publication date: September 23, 2010
    Applicant: Sloan Kettering Institute for Cancer Research
    Inventors: Jimmy Andrew Rotolo, Richard Kolesnick, Renata Pasqualini, Wadih Arap